UNCY Unicycive Therapeutics Inc.

FDA Catalyst Company
0.8
+0.05  (+6%)
Previous Close 0.75
Open 0.77
52 Week Low 0.624
52 Week High 8.73
Market Cap $11,953,327
Shares 15,020,517
Float 9,021,619
Enterprise Value $-5,729,639
Volume 17,259
Av. Daily Volume 94,472
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Maxim Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/16/2022
Roth Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/09/2021

Latest News

  1. On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in second quarter 2022

    Plans to initiate Phase 1 study for UNI-494 in second half of 2022

    LOS ALTOS, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2022 and provided a business update.

    Management Commentary

    "Throughout the first quarter, we continued to make meaningful progress to advance and expand the clinical development of our lead product candidates. We are on track to start our pivotal bioequivalence trial of Renazorb…

    View Full Article
  2. LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that there will be a Key Opinion Leader (KOL) Event discussing "Novel Treatments in Kidney Disease" with leading physician and thought leader, Glenn Chertow, M.D., MPH, Professor of Medicine at Stanford University School of Medicine and, by courtesy, Professor of Epidemiology and Population Health. Dr. Chertow also serves as a member of Unicycive Therapeutics' Scientific Advisory Board. The event will be moderated by Elemer Piros, Ph.D., Senior Biotechnology Analyst at ROTH Capital, who covers Unicycive Therapeutics.

    Event Details:

    Title:
    View Full Article
  3. On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022

    Plans to initiate Phase 1 study for UNI-494 in second half of 2022

    LOS ALTOS, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2021 and provided a business update.

    "The considerable progress we made throughout 2021 puts us in a strong position to execute on our strategy to advance our clinical development programs to address two important renal diseases where current treatment options are suboptimal…

    View Full Article
  4. LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Unicycive team, together with the Company's Chief Executive Officer, Shalabh Gupta, M.D., will recognize National Kidney Month and celebrate Unicycive's July 2021 listing on the Nasdaq Stock Market by ringing the Closing Bell at Nasdaq MarketSite in Times Square, New York City. The bell ringing will take place, March 29, 2022, at 4:00 p.m. ET.

    The ceremony will begin at approximately 3:45 PM Eastern time and can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

    "We are delighted to ring the Nasdaq closing…

    View Full Article
  5. LOS ALTOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that two in-vivo data sets highlighting the safety and comparative efficacy of the Company's proprietary product candidate, Renazorb (lanthanum dioxycarbonate), were accepted for presentation at the upcoming European Renal Association Congress (ERA 2022) taking place from May 19-22, 2022 in Paris, France and virtually.

    The following data will be presented at ERA 2022:

    Title: Lanthanum Dioxycarbonate Is Safe in Rats
    Format: Poster presentation
    Date/Time: May 19, 2022 from 8:00 am – 12:34 pm (Central European Standard Time)
       
    Title: Fast
    View Full Article
View All Unicycive Therapeutics Inc. News